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Background: This study aimed to investigate the effect of polycystic ovary syndrome (PCOS) on the association of
aromatase activity assessed by estradiol-to-testosterone ratio (E2/T) with body mass index (BMI) in women.
Methods: This was a cohort study in five centers for reproductive medicine in China. Data were collected from July
2012 to December 2013. PCOS patients (n = 785) and non PCOS, healthy, age-matched controls (n = 297) were
included. Plasma sex hormones including estradiol (E2), testosterone (T), follicle stimulating hormone (FSH), and
luteinizing hormone (LH) were measured by ELISA, together with BMI and E2/T being calculated, on the third day
of the menstrual cycle. Aromatase activity in PCOS patients with different BMI, T and E2 levels were compared.
Results: E2/T was significantly lower (P < 0.05) while BMI was significantly increased (P < 0.05) in PCOS than non-PCOS.
No significant difference was observed in E2/T among different BMI subgroups of either PCOS or control. Ovarian
aromatase activity was decreased in PCOS patients which was independent of BMI. Hyperestrogen promoted ovarian
aromatase activity, while hyperandrogen inhibited such activity, both in a dose-dependent, biphasic manner.
Conclusions: Ovarian aromatase activity was lower in PCOS, which was independent of BMI. New therapeutic
strategies can be developed by targeting aromatase activity for treating PCOS women, especially those with obesity.
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Polycystic ovary syndrome (PCOS) is a heterogeneous
disorder characterized by dysfunction of gonadal axis
and systemic nerve endocrine metabolic network [1],
with a prevalence of up to 10% in women of reproduct-
ive age [2,3]. Furthermore, this number may underesti-
mate the severity of the situation as many women with
PCOS in the community remain undiagnosed [4]. PCOS
has significant and diverse clinical implications including
reproductive, endocrine and metabolic abnormalities
such as hyperandrogenism and obesity [3]. Obesity, par-
ticularly abdominal obesity, is one of the independent
factors aggravating the PCOS endocrine disorders, as* Correspondence: xijun1025@163.com; yongwang@nju.edu.cn
†Equal contributors
1First Clinical Medicine College, Nanjing University of Chinese Medicine,
Nanjing 210046, China
2State Key Laboratory of Chemistry for Life Science and Jiangsu Key
Laboratory of Molecular Medicine, Medical School of Nanjing University,
Nanjing 210093, China
Full list of author information is available at the end of the article
© 2015 Chen et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.subcutaneous abdominal adipose tissues and the liver
tissues contribute to extragonadal aromatization [5].
Aromatase, a product of the CYP19 gene [6], is a
member of the cytochrome P450 family [7]. Aromatase
is a rate-limiting enzyme that catalyzes the conversion of
androgens (androstenedione and testosterone) to estro-
gens (estrone and estradiol) during steroidogenesis [8].
In ovaries, estradiol is generated by converting C19 andro-
gens derived from theca cells under the influence of aro-
matase produced by granulosa cells [9]. Consequently, the
ratio of estradiol (E2) to testosterone (T) has been used to
evaluate aromatase activity [10,11]. Multiple studies have
reported a dysfunctional P450-aromatase activity in PCOS
women. However, whether the abnormality is caused by
hyperfunction or insufficiency of the enzyme remains un-
known [12-16]. The nature of the interaction between
ovarian aromatase activity and PCOS in women has been
controversial, and the impact of weight gain on aromatase
activity as well as E2 levels is unknown.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Biochemical data from PCOS and non-PCOS groups
P (n = 785) non P (n = 297) P
BMI (kg/m2) 23.87 ± 4.85a 22.30 ± 3.27 <0.001
E2 (pmol/L) 254.81 ± 169.20
a 219.73 ± 166.32 0.002
T (nmol/L) 2.60 ± 1.58a 1.20 ± 0.70 <0.001
E2/T 0.10 (0.06-0.16)
a 0.16 (0.10-0.29) <0.001
FSH (mIU/L) 5.98 ± 2.93a 6.43 ± 2.17 0.006
LH (mIU/L) 11.90 ± 8.31a 5.37 ± 3.80 <0.001
FSH/LH 0.53 (0.36-0.91)a 1.41 (1.02-2.05) <0.001
Data is shown as means ± SD or median and interquartile ranges.
aPCOS group compared with non-PCOS group, P < 0.05 suggests significantly
different.
P: PCOS group, non P: non-PCOS group, BMI: body mass index, E2: estradiol,
T: testosterone, FSH: follicle-stimulating hormone, LH: luteinizing hormone.
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We designed a cohort study which included 1082 indi-
viduals from five clinical centers (785 PCOS and 297
age-matched non-PCOS) from July 2012 to December
2013. The study was approved by the Medical Ethics
Committee of the Medical School of Nanjing University,
Nanjing, China.
Inclusion and exclusion criteria
PCOS was diagnosed according to the 2006 Rotterdam
criteria [17]. PCOS may be confirmed if any two out of
the following three criteria are met and any other dis-
eases that cause anovulation or hyperandrogenism can
be excluded: (1) Oligovulation or anovulation, (2) Clin-
ical manifestation or biochemical evidence of hyperan-
drogenism, (3) Occurrence of PCO (at least 12 antral
follicles measuring 2–9 mm in diameter or the enlarge-
ment of an ovarian volume to more than 10 ml by trans-
vaginal ultrasound). The non-PCOS women were
selected from infertile couples if the infertility was at-
tributed to male factors in the study period. All the sub-
jects were between 20 and 35 years of age who had not
been taking hormone drugs such as contraceptives, ovu-
lation drugs, corticosteroids three months prior to inclu-
sion and who did not have serious heart, liver, renal, and
hematopoietic system diseases or malignant tumors.
Controls were recruited from healthy women with a
regular menstrual cycle, normal basal sex hormones
levels and absence of PCO on sonography.
Clinical and hormonal analyses
BMI was calculated as weight in kilograms divided by
the square of height in metres (kg/m2). Peripheral blood
samples were taken between 08:00–09:00 A.M. on the
third day of the menstrual cycle from all subjects after
overnight fasting and frozen at −80°C until assayed. Sex
hormones including E2, T, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) were measured by
ELISA (Beijing North Institute of Biological Technology
of China and the CIS Company of France). Intra- and
inter-assay coefficients of variation were 10% for all the
assays.
Grouping
Both the PCOS patients and non-PCOS subjects were
allocated to one of the three subgroups, namely the
obese subgroup (BMI ≥ 23 kg/m2), the normal-weightsubgroup (18.5 kg/m2 ≤ BMI < 23 kg/m2) and the under-
weight subgroup (BMI < 18.5 kg/m2), based on WHO
recommendations for the Asia-Pacific region [18].
PCOS patients were also divided into subgroups based
on the levels of T (T ≥ 2.44 nmol/L or T < 2.44 nmol/L)
and E2 levels (E2 > 293.6 pmol/L, 146.8 ≤ E2 ≤ 293.6 pmol/L,
or E2 < 146.8 pmol/L). The cuts-off were defined by nor-
mal laboratory reference values of reproductive medicine
centers.
Statistics
SAS version 9.0 (USA) software was used to match cases
and controls based on age. SPSS version 17 (SPSS, Chicago,
IL, USA) was used to process the data. Parameters were
described using mean ± standard deviation, or median ±
quartiles (for data not normally distributed) and the statis-
tical analyses were carried out by t-test and the rank-sum
test, respectively. Subgroup differences were calculated by
single-factor ANOVA. P < 0.05 was considered statistically
significant.
Results
Aromatase activity in PCOS
The base sex hormone differences between the PCOS
and non-PCOS subjects are summarized in Table 1.
PCOS patients showed significantly increased levels of
BMI, E2, T and LH, while their E2/T, FSH and FSH/LH
values were decreased compared with the non-PCOS
group.
Aromatase activity in women with different BMI with or
without PCOS
All the three PCOS subgroups manifested lower levels of
aromatase activity as compared to the corresponding
non-PCOS subgroups (Tables 1 and 2). Furthermore, no
significant differences in E2/T were observed in both
PCOS and non-PCOS subjects who had higher BMI
values. However, there were trends demonstrating rising
Table 2 Biochemical data of the subjects by BMI
BMI ≥ 23 kg/m2 18.5 kg/m2 ≤ BMI < 23 kg/m2 BMI < 18.5 kg/m2
P (n = 388) Non P (n = 103) P P (n = 343) Non P (n = 174) P P (n = 54) Non P (n = 20) P
BMI (kg/m2) 27.46 ± 4.39a,b,d 25.86 ± 2.66a,b 0.001 20.79 ± 1.24c 20.73 ± 1.23c 0.574 17.54 ± 0.87 17.67 ± 0.95 0.567
E2 (pmol/L) 247.95 ± 161.61
d 213.98 ± 164.51 0.048 258.49 ± 174.83d 222.07 ± 166.43 0.023 280.72 ± 185.52 228.93 ± 182.02 0.287
T (nmol/L) 2.60 ± 1.66d 1.23 ± 0.64b <0.001 2.57 ± 1.45d 1.21 ± 0.74c <0.001 2.81 ± 1.80d 0.86 ± 0.53 <0.001
E2/T 0.10 (0.06-0.15)
d 0.15 (0.09-0.24) 0.001 0.10 (0.06-0.16)d 0.17 (0.10-0.33) <0.001 0.09 (0.06-0.16)d 0.20 (0.11-0.65) <0.001
FSH (mIU/L) 5.74 ± 2.80a,d 6.40 ± 2.47 0.027 6.19 ± 2.79d 6.44 ± 2.06 0.045 6.40 ± 4.29 6.50 ± 1.46 0.916
LH (mIU/L) 10.16 ± 7.24a,b,d 5.22 ± 3.82 <0.001 13.24 ± 8.94b,d 5.39 ± 3.75 <0.001 15.90 ± 8.52d 5.98 ± 4.15 <0.001
FSH/LH 0.63 (0.42-1.03)b,d 1.46 (1.00-2.11) <0.001 0.47 (0.34-0.79)d 1.40 (1.05-2.01) <0.001 0.36 (0.36-0.51)d 1.38 (0.87-1.75) <0.001
Data is shown as means ± SD or median and interquartile ranges.
P: PCOS group compared with non-PCOS group.
aBMI ≥ 23 kg/m2 subgroup compared with 18.5 ≤ BMI < 23 kg/m2 subgroup, P < 0.05 means significantly different.
bBMI ≥ 23 kg/m2 subgroup compared with BMI < 18.5 kg/m2 subgroup, P < 0.05 means significantly different.
c18.5 ≤ BMI < 23 kg/m2 subgroup compared with BMI < 18.5 kg/m2 subgroup, P < 0.05 means significantly different.
dPCOS/non PCOS subgroups compared in the same BMI degree, P < 0.05 means significantly different.
P: PCOS group, non P: non PCOS group, BMI: body mass index, E2: estradiol, T: testosterone, FSH: follicle-stimulating hormone, LH: luteinizing hormone.
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values were increased.
Aromatase activity in PCOS patients with different E2 levels
Higher E2 levels correlated with a relatively enhanced
E2/T as well as T and LH levels but reduced BMI, FSH
and FSH/LH levels in women with PCOS (Table 3).
Aromatase activity in PCOS patients with different T levels
Hyperandrogenic PCOS patients had increased E2 levels
but their aromatase activity was markedly inhibited inde-
pendent of their BMI values. The gonadotropins FSH
and LH were both increased in people with higher T
levels. More precisely, a more pronounced increase of
LH was observed compared with FSH increase (Table 4).
Discussion
The human aromatase gene contains 10 exons and one
of them encodes nine alternative promoters to regulateTable 3 Biochemical data of PCOS patients by E2 levels
P (n = 785)
E2 > 293.6 pmol/L (n = 233) 146.8 ≤ E2 ≤ 293.
BMI (kg/m2) 23.32 ± 4.58b 23.92 ± 4.90
E2 (pmol/L) 455.73 ± 169.42
a,b 212.23 ± 40.01c
T (nmol/L) 2.97 ± 1.53a,b 2.59 ± 1.55c
E2/T 0.15 (0.11-0.24)
a,b 0.09 (0.06-0.14)c
FSH (mIU/L) 5.64 ± 3.60a 6.21 ± 2.55
LH (mIU/L) 12.76 ± 9.97b 12.12 ± 7.30c
FSH/LH 0.49 (0.33-0.73)b 0.52 (0.37-0.86)c
Data is shown as means ± SD or median and interquartile ranges.
P: compare in the three subgroups.
aE2 > 293.6 pmol/L subgroup compared with 146.8 ≤ E2 ≤ 293.6 pmol/L subgroup, P
bE2 > 293.6 pmol/L subgroup compared with E2 < 146.8 pmol/L subgroup, P < 0.05 m
c146.8 ≤ E2 ≤ 293.6 pmol/L subgroup compared with E2 < 146.8 pmol/L subgroup, P
P: PCOS group, non P: non PCOS group, BMI: body mass index, E2: estradiol, T: testotissue-specific expression, and the other nine are the
protein-coding exons [19]. Aromatase is expressed in spe-
cific cell populations of a variety of estrogen-producing
tissues, including placenta, ovaries, testes, skin, adipose
tissue, bone, brain, and vascular smooth muscle cells [19].
Importantly, aromatase in ovarian granulosa and lutein-
ized granulosa cells plays an important role for women of
reproductive age.
In this study, we aimed to discover the association be-
tween aromatase activity, obesity and sex hormones in a
large, well-described cohort of PCOS patients. However,
there is certain controversy regarding the correlation of
ovarian aromatase activity with PCOS [16]. The E2/T ra-
tio provides important information about aromatase ac-
tivity because conversion of androgens to estrogens is
mediated by CYP19, suggesting that the E2/T ratio may
be a direct marker of aromatase activity [20]. Based on
our data, PCOS is manifested by a typical abnormal hor-
mone pattern where the increase of LH, testosterone,6 pmol/L (n = 348) E2 < 146.8 pmol/L (n = 204) P
24.40 ± 5.03 0.034
97.96 ± 29.27 <0.001
2.19 ± 1.59 <0.001
0.05 (0.03-0.09) <0.001
5.97 ± 2.63 <0.001
10.55 ± 7.71 <0.001
0.64 (0.41-1.15) <0.001
< 0.05 means significantly different.
eans significantly different.
< 0.05 means significantly different.
sterone, FSH: follicle stimulating hormone, LH: luteinizing hormone.
Table 4 Biochemical data of the PCOS patients by T levels
P (n = 785)
T ≥ 2.44 nmol/L
(n = 364)
T < 2.44 nmol/L
(n = 421)
P
BMI (kg/m2) 23.35 ± 4.16 24.31 ± 5.34 0.076
E2 (pmol/L) 289.41 ± 179.69
a 224.89 ± 153.62 <0.001
T (nmol/L) 3.85 ± 1.46a 1.52 ± 0.55 <0.001
E2/T 0.07(0.05-0.11)
a 0.13 (0.09-0.20) <0.001
FSH (mIU/L) 6.29 ± 2.84a 5.71 ± 2.98 0.006
LH (mIU/L) 14.03 ± 9.03a 10.06 ± 7.15 <0.001
FSH/LH 0.48 (0.34-0.73)a 0.59 (0.39-1.10) <0.001
Data is shown as means ± SD or median and interquartile ranges.
aT ≥ 2.44 nmol/L subgroup compared with T < 2.44 nmol/L subgroup of PCOS,
P < 0.05 means significantly different.
P: PCOS group, non P: non PCOS group, BMI: body mass index, E2: estradiol,
T: testosterone, FSH: follicle-stimulating hormone, LH: luteinizing hormone.
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FSH, FSH/LH, and E2/T. We found a significant de-
crease of ovarian aromatase activity in women with
PCOS as compared to controls which is consistent with
previous work [8,16,21]. In the polycystic ovary, theca
cells synthesize more androgens than the corresponding
cells in a normal ovary. In contrast, granulosa cells in
the polycystic ovary have a lower aromatase activity,
which results in an imbalance in the production of estro-
gen and androgen. An earlier research by Soderlund and
co-workers found no gross deletions or insertions after
PCR amplification of the nine exons of the P450 arom
gene from the peripheral blood leukocytes of 25 PCOS
patients [22]. But this cannot preclude the importance of
an aromatase disorder in the etiology of PCOS, as there
may exist causative mutations in the untranslated re-
gions or within introns.
There is evidence that obesity, particularly abdominal
obesity, exacerbates both the clinical and endocrine fea-
tures of PCOS [23] which demonstrates significantly
more serious insulin resistance in these individuals than
normal-weight counterparts [24]. Although obesity is
not included in the diagnostic criteria for PCOS, 35% to
80% of PCOS women, depending on the setting of the
study and the ethnic characteristics of the patients, are
commonly overweight (BMI above 25 kg/m2) or obese
(BMI above 30 kg/m2) [25]. Our findings associated
higher BMI with PCOS but no concomitant change of
E2/T was observed. It is reported that estrogen has the
capacity to favorably regulate body composition and glu-
cose homeostasis to prevent diet-induced obesity [26].
Aromatase expression in the ovarian follicle is also re-
sponsible for the cyclic changes in serum estradiol levels
and the modulation of the structure and function of the
female reproductive tract and is essential for the sur-
vival, fertilization and implantation of oocytes. PCOS
promotes a hyperestrogenic state. In this research, PCOSwith high estradiol levels led to more serious hyperan-
drogenism but with relatively elevated levels of E2/T.
This is consistent with a previous study showing that
higher estradiol levels are caused by increased RNA ex-
pression of granulosa cell aromatase and its activity [27].
Nevertheless, high testosterone levels of PCOS inhib-
ited aromatase activity. We hypothesize that androgen
can dose-dependently affect aromatase activity directly,
or indirectly by regulating other factors such as E2 and
LH. One report suggests that early exposure of females
to androgen induces sex-specific organizational changes
of aromatase expression in the preoptic area [28].
Hyperinsulinemia and insulin resistance play a role in
the pathogenesis of PCOS. Analyzing existing studies,
the relationship between insulin and activity of cyto-
chrome P450 family has been explored. La Marca gave a
direct demonstration that decreasing insulin with metfor-
min led to a reduction in stimulated ovarian P450c17α ac-
tivity in PCOS and Nestler JE’s study showed the similar
result in lean PCOS [29,30]. Whether P450 aromatase ac-
tivity may be dependent on insulin resistance will be in-
vestigated in our follow-up work.
PCOS is a common ovulatory disorder in young
women, which affects 5-10% of the population and re-
sults in infertility due to anovulation [31]. Although the
pathogenesis of PCOS is still unclear, the role of hyper-
androgenism in the pathophysiology of PCOS has been
established but not clearly. Oral contraceptives, such as
ethinylestradiol and cyproterone acetate tablets, drospir-
enone and ethinylestradiol tablets, have been used in the
clinic to reduce hyperandrogen and to suppress follicular
development. Letrozole, an aromatase inhibitor, can in-
duce ovulation in PCOS so that a normal serum andro-
gen level can be maintained by blocking the early low
estrogen negative feedback. Generation and metabolism
of androgen is directly related to aromatase activity.
Along this line, aromatase-agonist-like-drugs perhaps
can directly induce follicular development and shorten
the treatment course of PCOS women irrespective of the
original hyperandrogen state.
Study limitation
We checked controls for PCOS features (PCOM, hyper-
androgenism, oligo-anovulation) in this study. Testoster-
one was the only androgen that was measured in our
study and other androgens such as androstenedione and
dehydroepiandrosterone sulfate do not be analyzed be-
cause of the limitation of research funding.
Conclusion
Taken together, our results showed that ovarian aromatase
activity in PCOS was decreased which was independent of
BMI. Hyperestrogen promoted ovarian aromatase activity
which could be inhibited by hyperandrogenism in a dose-
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correlation.
In both normal women and PCOS patients, estrogen
levels negatively correlated to BMI. Aromatase, the mas-
ter convertor of androgen to estrogen, can regulate the
estradiol-to-testosterone ratio and thereby regulates BMI.
Thus, enhancing aromatase activity may become an opti-
mized strategy for developing therapies for PCOS women,
especially those with obesity.
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